Determine the necessary mass, volume, or concentration for preparing a solution.
MeTC7 - ≥98% , CAS No.1817841-22-7
Zu bestellen verfügbar
GRADE & PURITY ≥98%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
🌎 Ship to: United States
224,000+ Forschungsprodukte · Triple ISO certified · COA & SDS für jedes Produkt verfügbar · Versand am selben Tag auf Lager
Why this grade
≥98% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Übersicht
MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC 50 value of 2.9 μM. MeTC7 shows good antitumor effects
In Vitro
MeTC7 (compound 5) shows potent VDR inhibition activity with an IC 50 value of 2.9 μM. MeTC7 disrupts the VDR-Ligand-binding domain in Silico. MeTC7 (250 nM; 18 h) suppresses RXRα and Importin-4 expressions in the ovarian cancer cell-line. MeTC7 (250 nM; 18 h) inhibits the viability of ovarian cancer cells and induces PARP1 cleavage. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: 2008 cells Concentration: 250 nM Incubation Time: 18, 12 h Result: Reduced the expression of RXR-α, Importin-4 and increased cleaved PARP1 expression in 2008 cells. Cell Viability AssayCell Line: SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines Concentration: 0, 0.25, 0.5, 0.75, 1.0, 1.25 μM Incubation Time: 24 h Result: Reduced the viability of SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines.
In Vivo
MeTC7 (compound 5) (i.p.; 10 mg/kg) reduces the growth of the spontaneous transgenic TH-MYCN neuroblastoma and xenografts in vivo . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 10 mg/kg Administration: IP Result: Reduced the growth of xenografts derived from ovarian cancer, medulloblastoma, and pancreatic cancer cells. Inhibited the growth of neuroblastoma cells and Xenografts. Reduced MYCN expression and blocked the growth of TH-MYCN transgene-driven spontaneous neuroblastoma.
Form:Solid
IC50& Target:IC50: 2.9 μM (VDR)
Specifications
Spezifikationen & Reinheit
≥98%
Biochemische und physiologische Mechanismen
MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC 50 value of 2.9 μM. MeTC7 shows good antitumor effects.
Storage
Store at -20°C
Verschickt in
Ice chest + Ice pads
Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.
Aktionsart
ANTAGONIST
Reinheit
≥98%
Namen und Kennungen
| Molekulargewicht | 618.65 |
|---|
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Zertifikate (CoA, COO, BSE/TSE und Analyse-Diagramm)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemische und physikalische Eigenschaften
| Löslichkeit | DMSO : 16.67 mg/mL (26.95 mM; ultrasonic and warming and heat to 60°C) |
|---|
Lösungsrechner
Bewertungen
Kundenbewertungen
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.